![Show Menu](styles/mobile-menu.png)
![Page Background](./../common/page-substrates/page0039.png)
39
risedronate for Paget's disease. N Engl J Med.
2005;353:898.
49.
Ralston SH, Langston AL, Reid IR. Pathogenesis
and management of Paget's disease of bone.
Lancet. 2008;372:155.
50.
Woitge HW,Oberwittler H,
Heichel S.
Short
and long-term effects of ibandronate treatment
on bone turnover in Paget disease of bone.
Clin Chem2000;46:684-90.
51.
Reid IR, Miller P, Lyles K, Fraser W, Brown JP,
Saidi Y, et al. Comparison of a single infusion of
zoledronic acid with risedronate for Paget's
disease. N Engl J Med 2005;353:898-908.
52.
Reid IR.Pharmacotherapy of Paget's disease of
bone
. Expert Opin Pharmacother2012;13:637-46.
53.
Langston AL,Campbell MK,
Fraser WD,
MacLennan GS, Selby PL, Ralston SH.
PRISMTrial Group. Randomized trial of
intensive bisphosphonate treatment versus
symptomatic management in Paget's disease of
bone
. J Bone Miner Res2010;25:20-31.